Histone Deacetylase 6 Inhibition Exploits Selective Metabolic Vulnerabilities in LKB1 Mutant, KRAS Driven NSCLC.

doi:10.1016/j.jtho.2023.03.014

Article

Histone Deacetylase 6 Inhibition Exploits Selective Metabolic Vulnerabilities in LKB1 Mutant, KRAS Driven NSCLC.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Jul 2023

Zhang Hua, Nabel Christopher S, Li Dezhi, O'Connor Ruth Í, Crosby Caroline R, Chang Sarah M, Hao Yuan, Stanley Robyn, Sahu Soumyadip, Levin Daniel S, Chen Ting, Tang Sittinon, Huang Hsin-Yi, Meynardie Mary, Stephens Janaye, Sherman Fiona, Chafitz Alison, Costelloe Naoise, Rodrigues Daniel A, Fogarty Hilda, Kiernan Miranda G, Cronin Fiona, Papadopoulos Eleni, Ploszaj Magdalena, Weerasekara Vajira, Deng Jiehui, Kiely Patrick, Bardeesy Nabeel, Vander Heiden Matthew G, Chonghaile Triona Ni, Dowling Catríona M, Wong Kwok-Kin

Abstract excerpt

INTRODUCTION: In KRAS-mutant NSCLC, co-occurring alterations in LKB1 confer a negative prognosis compared with other mutations such as TP53. LKB1 is a tumor suppressor that coordinates several signaling pathways in response to energetic stress. Our recent work on pharmacologic and genetic inhibition of histone deacetylase 6 (HDAC6) revealed the impaired activity of numerous enzymes involved in glycolysis. On the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung

Histone Deacetylase 6 Inhibition Exploits Selective Metabolic Vulnerabilities in LKB1 Mutant, KRAS Driven NSCLC.

Abstract excerpt

Topics

Related research